Pramipexole/Ondansetron

N/A

Report date: 2026/05/02 20:00:18

Base Information

Drug NamePramipexole/Ondansetron
Drug Alias NameALTO-207CTC-501
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D3 receptor agonistsDopamine D4 receptor agonistsDopamine D2 receptor agonists +[4] 
TargetsDopamine D2 receptorDopamine D4 receptorDopamine D3 receptor +[4] 
Therapy Area/IndicationsDepressive Disorder, Treatment-ResistantDepressive Disorder, Major
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsYes Pramipexole Dihydrochloride HydrateOndansetron Hydrochloride
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesChase Therapeutics Corp
China Registration ClassN/A

Develop Information

Active CompaniesAlto Neuroscience IncChase Therapeutics Co
Inactive CompaniesN/A
Active IndicationsDepressive Disorder, Treatment-ResistantDepressive Disorder, Major
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A